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Ovarian cancer is the most lethal of all gynecological malignancies, due in part to the diagnosis at an advanced stage caused by the
lack of speciﬁc signs and symptoms and the absence of reliable tests for screening and early detection. Most patients will respond
initially to treatment but about 70% of them will suﬀer a recurrence. Therefore, new therapeutic modalities are urgently needed to
overcome chemoresistance observed in ovarian cancer patients. Evidence accumulates suggesting that the insulin/insulin growth
factor (IGF) pathways could act as a good therapeutic target in several cancers, including ovarian cancer. In this paper, we will
focus on the role of insulin/IGF in ovarian cancer tumorigenesis and treatment.
1.Introduction
Ovarian cancer is the leading cause of death among all
gynecological cancers in western countries. When compared
to other gynecological cancers, the fatality rate of ovarian
cancer surpasses that of cervical and endometrial cancers put
together [1]. This high death rate is due to the diagnosis at
an advanced stage in most patients caused by the relative
lack of speciﬁc signs and symptoms of the disease and
the lack of reliable tests for early detection. It is estimated
that this year in North America, 24 150 women will be
newly diagnosed with ovarian cancer and that 17 220
women will die of the disease [2]. Epithelial ovarian cancer
(EOC) constitutes 90% of ovarian malignancies and is
classiﬁed into distinct histologic categories including serous,
mucinous, endometrioid, clear cell, transitional, mixed, and
undiﬀerentiated subtypes [3]. Nowadays, data suggest that
the cell of origin for an important proportion of high-grade
pelvic serous carcinomas, including the ovary, is derived
from the distal fallopian tube [2].
Although most patients with EOC experience a rea-
sonable initial clinical response to debulking surgery and
chemotherapy, the majority of these patients will not be
cured. Approximately 70% will experience a recurrence
and this chemoresistance is responsible for the majority
of ovarian cancer-related deaths [4]. Presently, there are
no available treatments capable of curing recurrent ovarian
carcinomas due to their rapid evolution into a chemoresis-
tant disease. It has therefore become essential to introduce
new therapeutic modalities that will change response to
treatment into cure and salvage these patients. Over the
last decade, accumulating data suggest that the insulin/IGF
pathway might be one such good therapeutic target in
cancers, including ovarian cancer. In this paper, we intend
to review the role of insulin/IGF pathway in ovarian cancer
and the various strategies to target it.
2. Physiological Roles of Insulinand
Insulin-LikeGrowthFactor
Insulin and Insulin-like growth factor (IGF) signaling regu-
latescellulargrowth,proliferation,metabolism,andsurvival.
Insulin was discovered in 1922 and is a crucial regulator of
metabolic pathways. It is under the tight control of blood
glucose levels and is excreted by the pancreas solely in
periods of rising blood glucose levels [5]. When released
by the beta-cells of the pancreas, insulin binds to receptors2 Journal of Oncology
on the surface of most cells. Hepatocytes, adipocytes, and
muscle cells are classic insulin responsive cells and express
high levels of insulin receptors. Insulin is primarily involved
in regulating metabolism but was also shown to have a
mitogenic eﬀect [6]. On the other hand, IGF signaling plays
a fundamental role in regulating embryonic growth and
regulates speciﬁc diﬀerentiation in most adult tissues [7].
I G Fi sam a j o rd o w n s t r e a mt a r g e to fg r o w t hh o r m o n e( G H )
and is essential for regulating growth and body size both in
the prenatal and postnatal stage [8]. The insulin and IGF-
I receptors, though separate gene products, are structurally
very similar. In addition, insulin and IGF-I are closely related
peptides. Amino acid similarities range between 40 and 85%
in diﬀerent domains with the highest degree of homology
being found in the tyrosine kinase domain [9].
Interestingly, the expression, signaling mechanisms, and
roles of members of the insulin/IGF family such as ligands,
receptors, binding proteins, and binding protein proteases
and their inhibitors have been elucidated in ovarian follicle
function in humans and other species. In vitro studies and
genetic approaches using mouse knockout models for IGF
family members have revealed that IGFs are key intraovarian
regulators of follicular growth, selection, atresia, cellular dif-
ferentiation, steroidogenesis, oocyte maturation, and cumu-
lusexpansion [10].Someoftheseactionsaresynergistic with
gonadotropins, although most are not sustainable with IGFs
alone and require gonadotropin actions. In fact, IGFs are
designated as copartners of gonadotropins. Moreover, recent
studies demonstrate that endocrine-disrupting chemicals
can compromise IGF activity and signaling in the ovarian
follicle,aﬀectingfolliculardevelopment,steroidogenesis,and
oocyte quality. The successful development of a healthy
oocyte and appropriate granulosa and theca cell steroido-
genesis on a cyclic basis are contingent on multiple factors,
including a properly functioning of intraovarian IGF system
[11]. Disruption of even one component of this system
can lead to abnormal follicular development and function.
Interaction of the IGF system with other growth factor
systems and ovarian peptides during follicular development
is still in early investigative stages.
3. InsulinandIGFsStructureandSignaling
3.1. Insulin and IGF Ligands. Insulin/IGF signaling system is
comprised of three ligands, IGF-I, IGF-II, and insulin itself.
These ligands interact with at least four receptors: the type
I IGF receptor (IGF-IR), the type II IGF receptor (IGF-
IIR), the insulin receptor (IR), hybrid receptors of IGF, and
insulin [12]. The circulating and biologically active form of
insulin ligands is a monomer consisting of two chains, an
A chain of 21 amino acids and a B chain of 30 amino acids
linked by two disulﬁde bridges [13]. On the other hand, IGFs
are small, single-chain polypeptide ligands (7-8kD) that are
derived from prepropeptides in a similar way to insulin, but
contain the C-peptide bridge between B and A chains that is
normally cleaved in insulin [14] .T h em a t u r eI G F - Ia n dI G F -
II peptides consist of B and A domains that are homologous
to B and A chain of insulin.
3.2. Insulin and IGFs Receptors and Signaling. Insulin action
is mediated through its receptor. The IR is a heterotetrameric
protein consisting of two extracellular α-subunits and two
transmembrane β-subunits. The binding of ligand to the α-
subunitsofIRstimulatestheintrinsictyrosinekinaseactivity
of the β-subunits of the receptor [15]. The ability of the
receptor to autophosphorylate and phosphorylate intracel-
lular substrates is essential for the mediation of the complex
cellular responses to insulin. The activated IR tyrosine
kinase phosphorylates several immediate substrates includ-
ing insulin receptor substrate proteins (IRS1-4), DOK4,
DOK5, SHC, Gab1, Cbl, APS, and signal regulatory protein
family. These adaptor proteins provide an interface between
the activated receptors and the downstream-located eﬀector
molecules. Insulin activates the mitogenic (via MAP kinases
and Erk1/2) and metabolic branches of insulin signaling,
the latter involving PI3 kinase, PKB/Akt, mTORC1, p70S6
kinase, as well as PLCγ [16–18]. There are two isoforms of
IR that are involved in diﬀerent cellular functions. These two
isoforms of IR are generated by alternative splicing of exon
11, giving rise to the B-isoform (IR-B) and A-isoform (IR-
A) [19]. They are expressed in a developmentally speciﬁc
manner, with high expression of IR-A in fetal tissues and
IR-B in adult tissues. Moreover, IGF-II binds IR-A with high
aﬃnity whereas IGF-I does not [20, 21].
The IGF-I and IGF-II ligands interact with an array
of cell receptors that may be present singly or in various
combinations on target cells. IGF-I has a twofold higher
aﬃnity for the IGF-IR than for the IR, most of the eﬀects
of IGF-I result from activation of the IGF-IR. IGF-I and IGF-
II interact with the IGF-IR, a transmembrane tyrosine kinase
that is structurally and functionally related to the IR [21, 22].
Homology between IR and IGF-IR ranges 45–65% and 60–
85% for the ligand binding, tyrosine kinase, and substrate
recruitment domains, respectively [23]. Ligand binding of
IGF-I or IGF-II to IGF-IR results in a conformational change
leading to transphosphorylation of one β-subunit by the
other. Activated IGF-IR recruits and phosphorylates adaptor
proteins belonging to the insulin receptor substrate (IRS)
family or SHC. The phosphorylated adaptor proteins then
serve as docking sites for other signaling molecules, resulting
in the activation of the downstream pathways. The IGF-
1R plays a central role in integrating signals of nutrition
and stress into energy shifts from energy expensive anabolic
p r o c e s s e ss u c ha sg r o w t ha n dr e p r o d u c t i o n[ 12, 24].
IGF-IIR is a multifunctional receptor that lacks an
intracellular signaling domain. It is known as the cation-
independent mannose-6-phosphatase receptor that binds to
a diverse group of mannose-6-phosphatase tagged proteins
for endosomal traﬃcking and degradation by the lyso-
some. The IGF-IIR or the cation-independent mannose-6-
phosphate receptor binds IGF-II and causes internalization
and subsequent clearance by the lysosome. IGF-IIR is
involved in the regulation of the extracellular concentration
of IGF-II [25].
Furthermore, many cells and tissues have hybrid recep-
tors assembled with one chain of the IGF-IR and one of
the IR. IGF-IR/IR-B hybrids have higher aﬃnity for IGF-I
whereas IGF-IR/IR-A hybrids have equal aﬃnity for IGF-IIJournal of Oncology 3
and insulin. Insulin binding to hybrid receptors initiates
similarcellularresponsesaswhenbindingtoIRorIGF-IR.In
bothcases,ligandbindingtotheirreceptorswillstimulatethe
activity of their intrinsic tyrosine kinase [26, 27]. However,
the exact role of hybrid receptors in signaling needs further
investigation.
3.3. Insulin-Like Growth Factor Binding Proteins (IGFBPs).
The IGFs action is under the control of six binding proteins.
IGFBPs are a family of secreted proteins that bind IGFs
with equal of greater aﬃnity than to IGF-IR. Six desig-
nated IGFBPs (1–6) have been isolated and characterized
so far in human and in a variety of vertebrate species.
These IGFBPs, with apparent molecular mass of 24–45kDa,
share a common domain organization. All of them have
a highly conserved N-terminal domain, a conserved C-
terminal domain, and a variable central linker domain. Most
IGFBPs function as carrier proteins for circulating IGFs and
regulate IGF turnover, transport, and tissue distribution,
thus determining the physiological concentration of IGFs.
Another important role of IGFBPs may be to help in the
storage of IGFs in the extracellular matrices of certain tissues
[28].
I G F B P sa r ep r o d u c e db yav a r i e t yo fb i o l o g i c a lt i s s u e s
and are thus found in various biological ﬂuids. Although
all six known IGFBPs belong to the same gene family,
several features distinguish IGFBPs from each other. IGFBP-
1, IGFBP-2, IGFBP-4, and IGFBP-6 inhibit IGFs actions by
preventing their binding to IGF receptors. In the circulation,
IGF-I and IGF-II are mainly bound to IGFBP-3, which is
the most abundant IGFBP in serum. Moreover, IGFBP-3 was
found not only to regulate the mitogenic actions of IGFs but
alsotoinhibittheirantiapoptotic eﬀect.Intriguingly, IGFBP-
3 has been localized in the nucleus, implying a more direct
transcriptional regulatory role, but the way extracellular
IGFBP-3 enters the cell remains largely unknown. IGFBPs
bind to IGF-I and IGF-II with the same aﬃnity as the
latter do with IGF-IR [29, 30]. Under diﬀerent physiological
conditions, the IGFBPs can either increase or decrease IGF
signaling, probably related to the fact that IGFBPs can
prolong the half-lives of IGFs but also can compete with
receptors for free IGF-I and IGF-II. However, IGFBP-1,
IGFBP-3, and IGFBP-5 can also mediate their eﬀects on the
target cells by an IGF independent pathway [31]. Table 1
summarizes the physiological roles of each insulin/IGF
family members.
An additional important variable is the presence of
speciﬁc IGFBP proteases. IGFBPs have been reported to be
proteolytically degraded by a variety of serine and matrix
metalloproteases. Proteolytic activity has been described for
IGFBP-2, IGFBP-3, IGFBP-4, and IGFBP-5. Since the IGFBP
fragments that are generated bind IGF-I weakly or not at
all, proteolysis is believed to play an important role in
controlling the bioavailability of IGF-I to receptors at the
cellular level. Although fragments that are generated usually
have reduced aﬃnity for the IGFs, the cleavage of IGFBP-3
generatesa 30-kDa fragmentwith relatively intact aﬃnity for
IGF-II [32]. This raises the possibility that these proteases
may function to release IGFs, making them available to
bind to receptors. Overall, the bioavailability and biological
activity of IGFs are modulated by these IGFBPs and their
proteases.
4.Insulin/IGFsinHumanCancers
IGF ligands, receptors, and IGFBPs have been shown to
play a critical role in the development and progression of
human cancers. Elevated plasma concentrations of IGF-I or
IGFBP-3 have been linked to a high risk for several types
of cancers including breast, prostate, and lung cancer [33–
35]. In addition, the expression levels of the IGF-IR and IR
are predictive of breast cancer outcome. Several studies have
also reported that inhibition of IGF-IR reduces metastasis
of various cancer cells emphasizing the importance of
IGF signaling in cancer progression. IGF/IGF-IR have been
studied extensively in metastatic colon, pancreatic, prostate,
and breast cancer [21, 36]. In many human cancers, there is
a strong association with dysregulated insulin/IGF signaling
pathway that has been extensively reviewed. However, the
role of insulin/IGF in ovarian cancer warrants further
description.
5. Components of the IGF Axis Expression in
Human Ovarian Cancer Risk
The ﬁrst study showing the expression of IGF-I mRNA
i no v a r i a nc a n c e rc e l l sa n dt i s s u e sw a sp u b l i s h e db a c ki n
1991 by Yee et al. [37]. They also reported several IGFBPs
and the IGF-IR expression by ovarian cancer cells. This
study suggested that all necessary components for an IGF-I-
mediated autocrine loop are present in ovarian cancer cells,
an observation that was also conﬁrmed in one of our early
studies using the OVCAR-3 cell line [38] .T w oo t h e rg r o u p s
described the expression of the IGF and insulin receptors
in ovarian tumors [39, 40]. During the same period, it
was reported that IGF-I levels were higher in cyst ﬂuid
from invasive malignant neoplasms compared to benign
tumors [41]. Later, another group conﬁrmed the presence
of the IGF-IR expression by immunohistochemistry (IHC)
in 100% of the ovarian carcinomas samples tested [42].
These initial studies opened the door to a widespread area
of research in ovarian cancer, indicating an involvement of
the insulin/IGF system in ovarian tumorigenesis.
5.1. Tissue Expression of the Insulin/IGF System in Ovarian
Cancer. A strong support for a role of IGF-I in ovarian
cancer progression came from a recent study by Brokaw
et al., who showed that high free IGF-I protein expression
in ovarian tumor tissue was independently associated with
the progression of ovarian cancer [43]. Moreover, IGF-I
mRNA expression was also associated with disease progres-
sion, implying that both endocrine and paracrine/autocrine
regulations of IGF-I activity are involved in ovarian cancer
[43]. Similarly, microarray expression proﬁles from 64 EOC
patients demonstrated that individual genes including IGF-
I, IGF-IR, and several genes downstream of the receptor
wereoverexpressed in tumors associatedwithan unfavorable
prognosis [44].4 Journal of Oncology
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Another member of the IGF family that seems to be
involved in ovarian cancer is the IGF-II. It has been reported
that IGF-II gene expression is increased more than 300-
fold in cancer tissues compared to normal ovarian surface
epithelium (NOSE) samples [45]. Interestingly, two studies
showed that IGF-II is associated with disease progression,
and proposed that it can be a predictor of poor survivals for
patients with EOC [45, 46]. Recently, the protein expression
of IGF-II mRNA-binding protein 3 (IGF2BP3, also known
as IMP3) was reported to be an independent marker for
reduced disease-speciﬁc survival in the rarely studied clear
cell carcinoma subtype of ovarian cancer [47].
Finally,itwasdemonstratedthatIGFBP-2relativemRNA
expression was 38-fold higher in ovarian cancer than in
NOSE [48]. A concomitant elevation in serum IGFBP-2 was
also observed in cancerous specimens, conveying the notion
that IGFBP-2 might represent a novel biomarker for detec-
tion and/or monitoring of EOC [48]. In opposition to the
above described studies, serum IGFBP-3 levels are decreased
in patients with ovarian cancer [49] and low IGFBP-3 levels
are associated with a higher risk for disease progression [50]
and poor survival [51] .T h es t u d i e sm e n t i o n e da b o v ea r e
detailed in Table 2.
5.2. Circulating Levels of the Insulin/IGF System in Ovarian
Cancer. In the same order of idea, a lot of eﬀorts were
made to verify the use of certain components of the IGF
system expression as predictive markers for ovarian cancer.
Thus, IGFBP-2 levels were determined in the serum of EOC
patientsandfoundtopositivelycorrelatewithcancerantigen
125 (CA125) [49], a widely used marker for ovarian cancer
follow-up.Overall,inretrospectivestudies,lowerIGF-Ilevels
were found in serum of disease patients versus controls
[41, 49, 52–55].
On the other hand, two recent prospective studies
reported a higher ovarian cancer risk among women aged
55 or less at time of diagnosis when comparing the top and
bottom tertile of IGF-I levels [56, 57]. However, in a recent
nested case-control study using data from three prospective
cohorts, namely, the Nurses’ Health Study (NHS), NHSII,
and the Women’s Health Study (WHS), no signiﬁcant
positive association between IGF related proteins (IGFBP-2,
IGFBP-3, and IGF-I) and ovarian cancer risk was found [58].
In general, studies aimed at determining an association
between ovarian cancer risks and circulating IGF concen-
trations have been few and inconsistent [59]( Table 3).
Clearly more investigative eﬀorts are needed to conﬁrm the
role of this hormone in ovarian cancer although biological
evidence suggests a mitogenic role of insulin and IGF-I in
the development of this disease.
6. Role of IGFFamilyinOvarian
Carcinogenesis:Proliferation, Angiogenesis,
Invasion,andMetastasis
A primary study using ovarian cancer cell lines implicated
IGF-II in cell adhesion and invasion through the stimulation
of the extracellular matrix glycoprotein tenascin-C [60].
Later, accumulating evidence depicted a role for IGF-I in
cellular proliferation, invasion, and angiogenesis. Firstly,
Shen et al. demonstrated an induction of KCl Cotransport
(KCC) in response to IGF-I in OVCAR-3 cells. This KCC
was necessary for IGF-I-induced cancer cell invasiveness and
proliferation [61].
Next, the induction of cell invasion and proliferation
by IGF-I occurred through phorpshorylation of AKT and
ERK1/2 in human ovarian cancer cells HRA [62]. IGF-I
also induced cyclooxygenase-2 (COX-2), a crucial player in
tumorangiogenesis,partlybyenhancingvascularendothelial
growth factor (VEGF) production [63]. This elevation of
COX-2 expression was followed by an augmentation of
prostaglandins E2 (PGE2) biosynthesis and was associated
with the activation of PI3K, MAPK, and PKC pathways.
Finally, IGF-I and insulin stimulated the migration of SKOV-
3 cells by favoring the urokinase-type plasminogen activator
(uPA) over the plasminogen activator inhibitor-1 (PAI-1)
through the PI3K/AKT pathway [64]. An induction of uPA is
linkedtoapoorprognosisandcorrelatestoamoreaggressive
phenotype of ovarian cancer [65–68]. As stated earlier,
IGFBP-2 is overexpressed in ovarian malignant tissues and
in the serum and cystic ﬂuid of ovarian cancer patients
[41, 48, 49, 69], indicating a role in the biology of ovarian
cancer. Indeed, it was reported that IGFBP-2 stimulated the
invasionofSKOV-3cellsusingtheMatrigelinvasionassay,an
eﬀect reversible by an attenuation of its expression by small
interference RNA (siRNA) [70].
On the contrary, two IGFBPs seem to have a suppressing
eﬀect on invasion, metastasis, and angiogenesis. Interest-
ingly, it was recently shown that IGFBP-3 inhibited cell
migration, invasion, and metastasis in the human ovarian
endometrioid carcinoma cell line OVRW59-P4 [51], an
observation that correlates with the low levels of IGFBP-3
expression in high tumor grade, advanced stage, and poor
survival in endometrioid carcinoma and EOC patients [50,
51]. IGFBP-5 function in angiogenesis was also studied in
a xenograft model of ovarian cancer. IGFBP-5 expression
prevented tumor growth and tumor vascularity, indicating
a tumor suppressor role in ovarian cancer [71].
7.Development of Inhibitorsof the
Insulin/IGF-I Pathways
The strategies to target IGF in cancer consist of (1) reducing
circulating ligand levels or bioactivity, (2) blocking recep-
tor function using receptor-speciﬁc antibodies or small-
molecule tyrosine kinase inhibitors, and (3) activating AMP-
activated protein kinase (AMPK) (see Figure 1).
7.1. Ligand-Targeted Approach. The ﬁrst-generation strate-
gies that included the use of somatostatin analogues to
diminish circulating IGF-I levels were unsuccessful [7]. It
was reported in one of the largest clinical trials that the
suppression of ligand levels was not achieved using this
approach [72], suggesting a failure of this particular strategy
rather than an evidence of a wrong targeting [7, 73]. This
targeting strategy has never been tested in ovarian cancer.6 Journal of Oncology
Table 2: Tissue expression modulations of the insulin/IGF system in ovarian cancer.
Insulin/IGF components No. of patients Modulation Reference
Free IGF-I mRNA and protein 215 EOC ↑ [43]
IGF-I, IGF-IR mRNA, and several genes downstream of the receptor 64 EOC ↑ [44]
IGF-II mRNA 109 EOC ↑ [45]
IGF-II mRNA 215 EOC ↑ [46]
IGFBP3 protein 128 clear cell carcinoma ↑ [47]
IGFBP-2 mRNA 113 EOC ↑ [48]
IGFBP-3 protein 147 EOC ↓ [50]
IGFBP-3 protein 35 endometrioid carcinoma ↓ [51]
EOC: epithelial ovarian cancer.
Table 3: Circulating protein levels of the insulin/IGF system in ovarian cancer.
Insulin/IGF components No. of patients Modulation Reference
IGFBP-2 20 EOC ↑ [49]
IGF-I 58 EOC ↓ [53]
IGF-I 24 EOC ↓ [52]
IGF-I 59 EOC ↓ [54]
IGF-I 9 EOC ↓ [55]
IGF-I 132 EOC (<55 yrs.) ↑ [56]
IGF-I 214 EOC (< 55 yrs.) ↑ [57]
IGF-I, IGFBP-2, IGFBP-3 222 EOC ↔ [58]
EOC: epithelial ovarian cancer.
7.2. Receptor-Speciﬁc Antibodies. T h e s ea g e n t sh a v eb e e n
designed to be highly speciﬁc for the IGF-IR; that is, they
do not bind to the insulin receptor. As described earlier,
there exist hybrid receptors whose expression depends on
the relative expression of the genes encoding the IGF-I
and insulin receptors [73]. Based on this theory of “half
receptors,” the novel antibody drug candidates have been
designed to act against IGF-IR and hybrid receptors. Many
have been studied in preclinical models and about a dozen
are being evaluated in clinical trials simultaneously [7, 73,
74].
The ﬁrst study targeting IGF-IR in ovarian cancer was
published in 2003 by Hongo et al., in which they used
a soluble form dominant negative of the type I IGF-IR
designated486/STOPinCaOV-3cells[75].ThissolubleIGF-
IR is a truncated receptor at the 486th amino acid, located
within the extramembranous α-subunit. They showed that
the 486/STOP expression could reverse transformed pheno-
type of the CaOV-3 in vitro and inhibit tumorigenicity in
vivo. Likewise, the administration of the 486/STOP recom-
binant protein retarded the tumor growth of CaOV-3 cells
in vivo.
Simultaneously, another group tested an antagonistic
monoclonal antibody designated EM164,speciﬁcto theIGF-
IR, in various cancer cell lines, including ovarian cancer
[76]. They demonstrated a reduction of IGF-I-stimulated
proliferation and survival of the human ovarian cancer
OVCAR-5 cells.
7.3. Receptor Kinase Inhibitors. Small molecule inhibitors
block IGF-IR activation by binding to the ATP-binding
pocket of the receptor [77]. Most of the developed tyrosine
kinase inhibitors have the side eﬀect of attenuating insulin
receptor signaling as well. However, despite this lack of
speciﬁcity, they were found to be active in preclinical models
and some are being evaluated in clinical trials [24, 74, 78].
There is a possibility that these agents might be more potent
anticancer drugs since insulin receptor present on malignant
cellsmayhaveanimportantroleaswellincarcinogenesis[7].
Inthelastcoupleofyears,studiestargetingIGForinsulin
pathways in ovarian cancer mostly used small molecule
IGF-IR kinase inhibitors. Indeed, our group reported an
inhibition of cell survival in response to NVP-AEW541
in two human epithelial ovarian cancer cell lines, namely,
OVCAR-3 and OVCAR-4 [38]. Interestingly, this eﬀect was
not reversible by the addition of recombinant IGF-I. We
furtherdemonstratedthatthisinhibitorsensitizedcellstothe
eﬀect of cisplatin, an eﬀect described in other types of cancer
c e l l sa sw e l l[ 77]. This observation is relevant to the clinical
application of the drug. Finally, NVP-AEW541 induced
apoptosis and decreased AKT activation. We also performed
a preliminary in vivo study using this small-molecule
inhibitor in a human ovarian cancer xenograft model that
gavepromisingresults[79].Weconﬁrmedourinvitroresults
using another IGF-IR kinase inhibitor produced by Bristol-
Myers-Squibb, BMS-536924. BMS-554417 is a derivative of
BMS-536924 and shares the same properties. Using the
OV202 cells, Haluska et al. showed an antiproliferative eﬀect
of BMS-554417 at an IC50 of 7,5μM[ 80]. Moreover, the
drug inhibited the phosphorylation of the IGF-IR, insulin
receptor, AKT, and ERK1/2 and also induced apoptosis. In
addition, treatment of OV202 with BMS-554417 stimulatedJournal of Oncology 7
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Figure 1: IR and IGF family signaling pathway. Upon the binding of the ligand, the activated receptor will undergo autophosphorylation
and in turn will phosphorylate IRS and SHC. Activated IRS will recruit GRB to the phosphorylated form of SHC adaptor protein. The
SHC-GRB complex will induce RAS and turn on the MAPK/ERK pathway, inducing cell proliferation and survival. Phospho-IRS will also
stimulate the PI3 kinase to phosphorylate AKT thus initiating its downstream eﬀectors such as mTOR, promoting translation, proliferation,
and cell survival. Generally, activated AKT will have an inhibitory eﬀect on TSC2, allowing Rheb-GDP to be converted to its GTP-bound
state, thereby activating mTOR and its downstream signaling molecules to promote cellular translation. Three diﬀerent potential targeted
therapies are underway of investigation in ovarian cancer, including IGF-IR antibodies, IGF-IR kinase inhibitors, and AMPK activators such
as metformin.
the phosphorylation of HER-2. Inversely, treatment with
the pan-HER inhibitor increased the phosphorylation of
IGF-IR, suggesting a reciprocal cross-talk mechanism [81].
Therefore, the combination of BMS-536924 and a pan-HER
inhibitor resulted in a synergistic antiproliferative eﬀect in
various ovarian cancer cell lines. A concomitant reduction
of AKT and ERK phosphorylation and apoptosis induction
were also demonstrated. Furthermore, HER receptor expres-
sioncouldconferresistancetoIGF-IR-targetedtherapyusing
breast cancer cells expressing HER-1 or HER-2. This suggests
that combining targeted therapies to the HER and IGF-I
familyofreceptorsmightbeaneﬀectivestrategytoovercome
potential clinical resistance to IGF-IR inhibitors.
Concurrently, we showed a dose and time-dependent
growth inhibition of human epithelial ovarian cancer cell
lines, the OVCAR-3 and OVCAR-4 in response to BMS-
536924 [82]. This eﬀect was partly mediated by AKT and the
ribosomal protein S6. BMS-536924 provoked cell apoptosis
as shown by the activation of PARP cleavage. We ﬁnally
showed that this IGF-IR kinase inhibitor could sensitize
cells to PARP inhibitors, possibly via the induction of DNA
damage as indicated by the increased phosphorylation of
histoneH2AX.ThisstudyreinforcedtheconceptthatIGF-IR
is a good therapeutic target in ovarian cancer. In addition, it
proposes that combination therapy using BMS-536924 with
aPARPinhibitormightbeaneﬀective strategy to circumvent
resistance to treatment in clinical settings.
7.4. Metformin. Another potential drug targeting agent
related to the insulin and/or IGF pathway is metformin.
Metformin is an oral biguanide widely used since the 1950s
for the treatment of type 2 diabetes, that lowers both
circulatingglucoseandinsulinlevels.Twopopulationstudies
provided preliminary evidence that metformin may reduce
cancer risk and improve prognosis in patients with type 2
diabetes[83,84].Importantly,recentdatademonstratedthat
the key mechanism of action of metformin is by activating
the AMPK-LKB1 pathway [85, 86]. Other AMPK activators
have been demonstrated to have growth inhibitory eﬀects
in various cancer cell types [87–89]. Therefore, metformin8 Journal of Oncology
might have two potential antineoplastic eﬀects: reducing
circulating insulin levels and directly inhibiting growth
through the AMPK-LKB1 pathway.
We published the original study evaluating the anti-
neoplastic eﬀect of metformin in human epithelial ovarian
cancer cell lines [90]. We demonstrated that metformin
decreased in a dose and time-dependent manner ovarian
cancer cells survival, an eﬀe c tp a r t l ym e d i a t e db yA M P K .
Moreover, metformin potentiated the eﬀect of cisplatin. The
activation of AMPK by metformin was associated with an
inhibition of downstream targets of AKT, such as phospho-
p70S6 and phospho-S6. These ﬁndings led us to evaluate
the potential applicability of metformin in the treatment of
ovarian cancer by testing it in preclinical animal models.
These experiments are currently underway of investigation
in our laboratory.
Only two other recent studies showed a cytotoxic eﬀect
of other AMPK activators. The ﬁrst one is C93, a synthetic
fatty acid synthase inhibitor that increased AMP/ATP ratio
in SKOV3 human ovarian cancer cells, thereby provoking
AMPK activation and leading to cell toxicity [91]. Using
compound C, a speciﬁc inhibitor of AMPK, the authors
clearly implicated AMPK in the cytotoxic action of C93.
Interestingly, these ﬁndings were conﬁrmed in vivo in
an SKOV3 xenograft mice model [91]. The second study
provided evidence that curcumin caused CaOV3 ovarian
cancer cell death through AMPK, suggesting that the latter
is a new molecular target of curcumin [92].
7.5. Clinical Trials. To the best of our knowledge, only
two clinical trials using targeted therapy against IGF-IR are
currently ongoing in ovarian cancer patients (clinicaltri-
als.gov identiﬁer: NCT00719212 and NCT00718523). Both
studies are testing the same human anti-IGF-IR human
monoclonal antibody, namely, the AMG-479 [74, 93] that
was previously tested clinically in other types of cancer
[94, 95]. The objective of the ﬁrst study is to verify whether
the addition of AMG-479 to paclitaxel and carboplatin in
ﬁrst line chemotherapy could improve the progression-free
survival in patients with optimally debulked FIGO stage III
and IV ovarian epithelial carcinoma. The second study aims
to obtain an estimate of the objective response rate (ORR)
of AMG-479 in patients with recurrent platinum-sensitive
ovarian epithelial carcinoma failing frontline chemotherapy.
The completion dates of both studies are estimated in 2015
and 2012, respectively.
8. Conclusion
All members of the IGF family are expressed in malignant
ovarian epithelial cells. On the other hand, circulating levels
of IGF have not been undoubtedly associated with ovarian
cancer risk or disease progression. However, a role of some
of the components of the IGF family, such as IGF-I and IGF-
IR, has been clearly involved in ovarian tumorigenesis. In
the past few years, various inhibitors of IGF-IR have been
developed, including AMPK activators. These were tested
in ovarian cancer in vitro and in vivo models, obtaining
promising results for the potential of this targeted strategy
in ovarian carcinoma, supported by the currently ongoing
clinical trials.
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